Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by National Cancer Institute (NCI).
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
University of Sheffield
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00072020
First received: November 4, 2003
Last updated: July 11, 2012
Last verified: January 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Zoledronate may delay or prevent the formation of bone metastases. It is not yet known whether chemotherapy and/or hormone therapy are more effective with or without zoledronate in preventing cancer recurrence and bone metastases in women with breast cancer.
PURPOSE: This randomized phase III trial is studying giving chemotherapy and/or hormone therapy together with zoledronate to see how well they work compared to chemotherapy and/or hormone therapy alone in preventing cancer recurrence and bone metastases in women with stage II or stage III breast cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Cancer Metastatic Cancer |
Drug: zoledronic acid Procedure: adjuvant therapy Procedure: neoadjuvant therapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Does Adjuvant Zoledronic Acid Reduce Recurrence in Patients With High Risk Localized Breast Cancer? |
Resource links provided by NLM:
Genetics Home Reference related topics:
breast cancer
Drug Information available for:
Zoledronic acid
U.S. FDA Resources
Further study details as provided by National Cancer Institute (NCI):
Primary Outcome Measures:
- Disease-free survival as assessed annually for 10 years [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Time to bone metastases as first recurrence assessed annually for 10 years [ Designated as safety issue: No ]
- Time to bone metastases per se as assessed annually for 10 years [ Designated as safety issue: No ]
- Time to distant metastases as assessed annually for 10 years [ Designated as safety issue: No ]
- Overall survival as assessed by final analysis at 10 years [ Designated as safety issue: No ]
- Skeletal-related events prior to development of bone metastases as assessed annually for 10 years [ Designated as safety issue: No ]
- Skeletal-related events following development of bone metastases as assessed annually for 10 years [ Designated as safety issue: No ]
- Safety and toxicity of zoledronic acid as assessed annually for 10 years [ Designated as safety issue: Yes ]
- Evaluation of the influence of prognostic factors (e.g., estrogen receptor or progesterone receptor [ER/PR] status, TNM stage, tumor grade, HER2/neu, and menopausal status) on treatment outcome [ Designated as safety issue: No ]
- Analysis of tumor-specific mutations, proteomics and gene expression changes in tumor cells [ Designated as safety issue: No ]
| Study Start Date: | August 2003 |
OBJECTIVES:
Primary
- Compare disease-free survival of women with stage II or III breast cancer at high risk of relapse treated with neoadjuvant or adjuvant chemotherapy and/or hormonal therapy with vs without zoledronate.
Secondary
- Compare time to bone metastases, as first recurrence, in patients treated with these regimens.
- Compare time to bone metastases, per se, in patients treated with these regimens.
- Compare time to distant metastases in patients treated with these regimens.
- Compare overall survival in patients treated with these regimens.
- Compare the reduction in skeletal-related events (fractures, spinal cord compression, radiotherapy to the bone, surgery to the bone, and hypercalcemia) before and after the development of bone metastases in patients treated with these regimens.
- Determine the safety and toxicity of zoledronate in patients treated with these regimens.
- Correlate prognostic factors, such as estrogen-receptor and progesterone-receptor status, TNM stage, tumor grade, HER2/neu status, and menopausal status with treatment outcome in patients treated with these regimens.
- Determine more specific prognostic indicators for the development of bone metastases and factors that are able to predict specific benefit from bisphosphonate treatment using proteomics, tissue micro-array, and other modern techniques in these patients.
OUTLINE: This is a randomized, open-label, parallel-group, multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive neoadjuvant or adjuvant chemotherapy and/or hormonal therapy. Patients also receive concurrent zoledronate IV over 15 minutes every 3-4 weeks for 6 doses, every 3 months for 8 doses, and then every 6 months for 5 doses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive neoadjuvant or adjuvant chemotherapy and/or hormonal therapy alone.
After completion of study treatment, patients are followed annually for 5 years.
PROJECTED ACCRUAL: A total of 3,300 patients (1,650 per treatment arm) will be accrued for this study within 3 years.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
Diagnosis of primary breast cancer, meeting 1 of the following staging criteria:
- Stage II
- Stage III
- T stage ≥ T1
Receiving OR scheduled to receive chemotherapy and/or endocrine therapy
For patients receiving neoadjuvant therapy
- Tumor > 5 cm (T3), features of locally advanced disease (T4), OR biopsy-proven lymph node involvement (N1)
- Scheduled to proceed to definitive surgery and/or radical radiotherapy with curative intent within 6 months of starting neoadjuvant therapy
- No more than 30 days between initiation of neoadjuvant therapy and start of study drug
For patients receiving adjuvant therapy
- Must have undergone complete primary tumor resection and treatment of axillary lymph nodes*
- Must have lymph node involvement
- No prior neoadjuvant therapy**
- No more than 60 days since prior definitive surgery NOTE: *Patients whose treatment plan includes further primary tumor resection and/or treatment of the axillary lymph nodes (e.g., clearance or radiotherapy) with curative intent after completion of chemotherapy are eligible provided the treatment is completed within 9 months of study entry
NOTE: **Preoperative endocrine therapy with a duration of < 30 days is not considered prior neoadjuvant therapy
- No evidence of recurrent or metastatic disease
- No history of breast cancer, except ductal carcinoma in situ or lobular carcinoma in situ
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age
- 18 and over
Sex
- Female
Menopausal status
- Premenopausal or postmenopausal
Performance status
- Karnofsky 80-100% OR
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Creatinine ≤ 1.5 times upper limit of normal
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No active dental problems, including dental abscess or infection of the jaw bone (e.g., maxilla or mandible)
- No prior or current diagnosis of osteonecrosis of the jaw
- No other malignancy within the past 5 years (including prior contralateral breast cancer) except nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix
No history of disease with influence on bone metabolism, including any of the following:
- Paget's disease of the bone
- Primary hyperparathyroidism
- Osteoporosis requiring treatment or likely to require treatment within the next 6 months
- No other severe physical or psychological disease that would preclude study compliance
- No known hypersensitivity to bisphosphonates
PRIOR CONCURRENT THERAPY:
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- See Disease Characteristics
Radiotherapy
- See Disease Characteristics
Surgery
- See Disease Characteristics
More than 4 weeks since prior and no concurrent dental or jaw surgery (e.g., extractions or implants)
- Dental fillings, teeth scaling and polishing, or minor gingival surgery within the past 4 weeks are allowed
Other
- More than 1 year since prior bisphosphonates
- More than 30 days since prior investigational drugs
- No concurrent investigational drugs (i.e., not locally approved for any indication)
Contacts and Locations More Information
Additional Information:
Publications:
Coleman R, Thorpe H, Cameron D, et al.: Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy first safety data from the AZURE trial (BIG01/04). [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-2080, S107, 2006.
| ClinicalTrials.gov Identifier: | NCT00072020 History of Changes |
| Other Study ID Numbers: | CDR0000335111, SHEFF-AZURE, EU-20315, ISRCTN79831382, BIG-1-04 |
| Study First Received: | November 4, 2003 |
| Last Updated: | July 11, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
bone metastases stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer stage IIIC breast cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasm Metastasis Neoplasms Neoplasms, Second Primary Neoplasms by Site Breast Diseases Skin Diseases Neoplastic Processes |
Pathologic Processes Adjuvants, Immunologic Zoledronic acid Diphosphonates Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions Bone Density Conservation Agents |
ClinicalTrials.gov processed this record on May 19, 2013